CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Publications Webcasts Algorithm Abstract Library Committee Members
 
HCC-Single Disease Content  
HCC Care Cascade Decision-Support Tool
 
Publications
 
Webcasts
HCC Epidemiology and Care Cascade Recommendations   Educational Webcast
New Advances in HCC Therapies   Educational Webcast
Slide Library
   Released: 2023
test
HCC Epidemiology and Care Cascade Recommendations
15 slides
 
 
   Released: 2022
test
New Advances in HCC Therapies
61 slides
 
 
 
 
Abstract Library
1.Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
 

Nat Rev Clin Oncol. 2024 Feb 29. doi: 10.1038/s41571-024-00868-0.Online ahead of print.

 

Josep M Llovet 1 2 3, Roser Pinyol 4, Mark Yarchoan 5 6, Amit G Singal 7, Thomas U Marron 8, Myron Schwartz 9, Eli Pikarsky 10, Masatoshi Kudo 11, Richard S Finn 12
 
2.Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab
 

Liver Int. 2024 May;44(5):1108-1125. doi: 10.1111/liv.15885.Epub 2024 Mar 22.
 
3.Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy
 

J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501. Online ahead of print.

 

N M Batt 1, B Rodrigues 1, S Bloom 1 2, R Sawhney 1 2, E S George 3, A Hodge 1 2, N Vootukuru 1, C McCrae 1, Surbhi Sood 3, S K Roberts 4 5, A Dev 6, S Bell 5 6, A Thompson 7 8, M C Ryan 7 8, W Kemp 4, P J Gow 9, Siddharth Sood 10, A J Nicoll 1 2
 
4.Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis
 

Clin Mol Hepatol. 2024 Apr 16. doi: 10.3350/cmh.2024.0109. Online ahead of print.

 

Harry Crane 1, Guy D Eslick 2, Cameron Gofton 1 3, Anjiya Shaikh 4, George Cholankeril 5, Mark Cheah 6, Jian-Hong Zhong 7, Gianluca Svegliati-Baroni 8, Alessandro Vitale 9, Beom Kyung Kim 10, Sang Hoon Ahn 10, Mi Na Kim 10, Simone Strasser 11, Jacob George 1
 
5.Diagnostic performance of non-invasive liver fibrosis scores in patients with early-intermediate hepatocellular carcinoma
 

J Cancer Res Clin Oncol. 2024 Apr 11;150(4):187. doi: 10.1007/s00432-024-05708-3.

 

Christopher Schrecker 1, Falko Schulze 2, Jörg Trojan 3, Wolf Otto Bechstein 4, Stefan Zeuzem 3, Christine Koch 5 6
 
6.Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib
 

Intern Emerg Med. 2024 Mar 29. doi: 10.1007/s11739-024-03578-8. Online ahead of print.

 

Bernardo Stefanini # 1, Francesco Tovoli # 2 3, Franco Trevisani 2 4, Mariarosaria Marseglia 3, Giovan Giuseppe Di Costanzo 5, Giuseppe Cabibbo 6, Rodolfo Sacco 7 8, Filippo Pellizzaro 9, Tiziana Pressiani 10, Rusi Chen 2, Francesca Romana Ponziani 11, Francesco Giuseppe Foschi 12, Giulia Magini 13, Alessandro Granito 2 3, Fabio Piscaglia 2 3; Italian Liver Cancer (ITA.LI.CA) group
 
7.Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma
 

World J Hepatol. 2024 Mar 27;16(3):393-404. doi: 10.4254/wjh.v16.i3.393.

 

Andrew Scott deLemos 1, Jing Zhao 2, Milin Patel 3, Banks Kooken 3, Karan Mathur 4, Hieu Minh Nguyen 5, Areej Mazhar 6, Maggie McCarter 2, Heather Burney 7, Carla Kettler 7, Naga Chalasani 8, Samer Gawrieh 8
 
8.Medicaid expansion and palliative care for advanced-stage liver cancer
 

J Gastrointest Surg. 2024 Apr;28(4):434-441. doi: 10.1016/j.gassur.2024.01.042.Epub 2024 Feb 12.

 

Henrique A Lima 1, Parit Mavani 2, Muhammad Musaab Munir 2, Yutaka Endo 2, Selamawit Woldesenbet 2, Muhammad Muntazir Mehdi Khan 2, Karol Rawicz-Pruszynski 3, Usama Waqar 4, Erryk Katayama 2, Vivian Resende 1, Mujtaba Khalil 2, Timothy M Pawlik 5
 
9.Hepatocellular Carcinoma: Advances in Systemic Therapy
 

Semin Intervent Radiol. 2024 Mar 14;41(1):56-62. doi: 10.1055/s-0044-1779713.eCollection 2024 Feb.

 

Insija Ilyas Selene 1, Merve Ozen 2, Reema A Patel 2
 
10.Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis
 

Clin Gastroenterol Hepatol. 2024 Apr;22(4):778-788.e7. doi: 10.1016/j.cgh.2023.11.020.Epub 2023 Dec 5.

 

Binu V John 1, Yangyang Dang 2, David E Kaplan 3, Janice H Jou 4, Tamar H Taddei 5, Seth A Spector 6, Paul Martin 7, Dustin R Bastaich 2, Hann-Hsiang Chao 8, Bassam Dahman 2
 
11.No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC
 

Liver Int. 2024 Apr;44(4):931-943. doi: 10.1111/liv.15833. Epub 2024 Jan 30.

 

Francisca-Dora Copil 1, Claudia Campani 2, Marie Lequoy 3, Philippe Sultanik 1, Lorraine Blaise 4, Mathilde Wagner 5, Nathalie Ganne-Carrié 2 4, Violaine Ozenne 3, Dominique Thabut 1 6, Jean-Charles Nault 2 4, Vlad Ratziu 1 6, Manon Allaire 1 2 7
 
12.Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
 

J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745. Online ahead of print.

 

John D Gordan 1, Erin B Kennedy 2, Ghassan K Abou-Alfa 3 4, Eliza Beal 5, Richard S Finn 6, Terence P Gade 7, Laura Goff 8, Shilpi Gupta 9, Jennifer Guy 10, Hang T Hoang 11, Renuka Iyer 12, Ishmael Jaiyesimi 13, Minaxi Jhawer 14, Asha Karippot 15, Ahmed O Kaseb 16, R Kate Kelley 1, Jeremy Kortmansky 17, Andrea Leaf 18, William M Remak 19, Davendra P S Sohal 20, Tamar H Taddei 21, Andrea Wilson Woods 22, Mark Yarchoan 23, Michal G Rose 24
 
13.Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality
 

Br J Cancer. 2024 Mar 18. doi: 10.1038/s41416-024-02645-3. Online ahead of print.

 

Anya Burton 1 2, Jennifer Wilburn 3, Robert J Driver 4, David Wallace 5 6, Sean McPhail 3, Tim J S Cross 7, Ian A Rowe 4, Aileen Marshall 8
 
14.Mechanisms of drug resistance in HCC
 

Hepatology. 2024 Apr 1;79(4):926-940. doi: 10.1097/HEP.0000000000000237.Epub 2023 Jan 3.

 

Alexandra D Ladd 1, Sergio Duarte 1, Ilyas Sahin 2, Ali Zarrinpar 1
 
15.Implementation of a National Liver Review Board for exception requests in the United States: A 2-year monitoring report
 

Liver Transpl. 2024 Apr 1;30(4):367-375. doi: 10.1097/LVT.0000000000000248.Epub 2023 Aug 29.

 

Allison J Kwong 1, Julia Foutz 2, Matt Cafarella 2, Scott W Biggins 3, Neil D Shah 4, James Eason 5, Emily R Perito 6, James Pomposelli 7, James Trotter 8
 
16.a-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
 

Int J Cancer. 2024 Mar 15;154(6):1043-1056. doi: 10.1002/ijc.34799. Epub 2023 Nov 23.

 

Federico Rossari 1 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Changhoon Yoo 7, Jaekyung Cheon 8, Fabian Finkelmeier 9, Ho Yeong Lim 10, José Presa 11, Gianluca Masi 12 13, Francesca Bergamo 14, Elisabeth Amadeo 1, Francesco Vitiello 1, Takashi Kumada 15, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 8, Vera Himmelsbach 9, Massimo Iavarone 16, Giuseppe Cabibbo 17, Margarida Montes 11, Francesco Giuseppe Foschi 18, Caterina Vivaldi 12 13, Caterina Soldà 14, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 9, Masashi Hirooka 19, Kazuya Kariyama 20, Joji Tani 21, Masanori Atsukawa 22, Koichi Takaguchi 23, Ei Itobayashi 24, Shinya Fukunishi 25, Kunihiko Tsuji 26, Toru Ishikawa 27, Kazuto Tajiri 28, Hironori Ochi 29, Satoshi Yasuda 30, Hidenori Toyoda 30, Chikara Ogawa 31, Takashi Nishimura 32, Takeshi Hatanaka 33, Satoru Kakizaki 34, Noritomo Shimada 35, Kazuhito Kawata 36, Atsushi Hiraoka 37, Fujimasa Tada 37, Hideko Ohama 37, Kazuhiro Nouso 20, Asahiro Morishita 21, Akemi Tsutsui 23, Takuya Nagano 23, Norio Itokawa 22, Tomomi Okubo 22, Michitaka Imai 27, Hisashi Kosaka 38, Atsushi Naganuma 39, Yohei Koizumi 

17.Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy
 

J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501. Online ahead of print.

 

N M Batt 1, B Rodrigues 1, S Bloom 1 2, R Sawhney 1 2, E S George 3, A Hodge 1 2, N Vootukuru 1, C McCrae 1, Surbhi Sood 3, S K Roberts 4 5, A Dev 6, S Bell 5 6, A Thompson 7 8, M C Ryan 7 8, W Kemp 4, P J Gow 9, Siddharth Sood 10, A J Nicoll 1 2
 
18.Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
 

Nat Rev Clin Oncol. 2024 Feb 29. doi: 10.1038/s41571-024-00868-0.Online ahead of print.

 

Josep M Llovet 1 2 3, Roser Pinyol 4, Mark Yarchoan 5 6, Amit G Singal 7, Thomas U Marron 8, Myron Schwartz 9, Eli Pikarsky 10, Masatoshi Kudo 11, Richard S Finn 12
 
19.ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer
 

Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801. Online ahead of print.

 

Zhenwei Peng 1 2, Guangyan Wei 1 2, Pinzhu Huang 2, Heansika Matta 2, Gao Wen 2, Ping An 2, Shuangshuang Zhao 2, Yi Lin 2, Li Tan 2 3, Kahini Vaid 2, Disha Skelton-Badlani 2, Imad Nasser 4, Grant Budas 5, David Lopez 5, Li Li 5, David Breckenridge 5, Rob Myers 5, John McHutchison 5, Ming Kuang 3 6, Yury V Popov 2
 
20.Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases
 

Curr Med Res Opin. 2024 Feb 28:1-13. doi: 10.1080/03007995.2024.2322057.Online ahead of print.

 

Keziah Cook 1, Deepshekhar Gupta 1, Yunjuan Liu 1, Chris Miller-Rosales 1, Fangzhou Wei 1, Edward Tuttle 1, Steven C Katz 2 3, Richard Marshak 2, Alexander Y Kim 2
 
21.Geographic Disparities in Access to Liver Transplant for Advanced Cirrhosis: Time to Ring the Alarm!
 

Am J Transplant. 2024 Feb 20:S1600-6135(24)00160-6. doi: 10.1016/j.ajt.2024.02.018.Online ahead of print.

 

Jasmohan S Bajaj 1, Ashok Choudhury 2, Vinay Kumaran 3, Florence Wong 4, Wai Kay Seto 5, Mario Reis Alvares-Da-Silva 6, Hailemichael Desalgn 7, Peter C Hayes 8, Ramazan Idilman 9, Mark Topazian 7, Aldo Torre 10, Qing Xie 11, Jacob George 12, Patrick S Kamath 13
 
22.Immune checkpoint inhibitors in liver transplantation: Current practice, challenges and opportunities
 

Liver Transpl. 2024 Feb 13. doi: 10.1097/LVT.0000000000000350. Online ahead of print.

 

Sean P Martin 1 2, Neil Mehta 3, Juliet Emamaullee 1
 
23.Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape
 

Cancers (Basel). 2024 Feb 4;16(3):666. doi: 10.3390/cancers16030666.

 

Emily Kinsey 1 2 3 4, Hannah M Lee 3 4 5
 
24.FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
 

Clin Cancer Res. 2024 Jan 17;30(2):269-273.doi: 10.1158/1078-0432.CCR-23-2124.

 

Timil H Patel 1, Jamie R Brewer 1, Jiaxin Fan 2, Joyce Cheng 2, Yuan-Li Shen 2, Yue Xiang 3, Hong Zhao 3, Steven J Lemery 1 4, Richard Pazdur 1 4, Paul G Kluetz 1 4, Lola A Fashoyin-Aje 1 4
 
25.Outcomes of Living Donor Liver Transplantation Compared with Deceased Donor Liver Transplantation
 

Surg Clin North Am. 2024 Feb;104(1):79-88. doi: 10.1016/j.suc.2023.08.007.Epub 2023 Sep 23.

 

Kiara A Tulla 1, Francis J Tinney Jr 1, Andrew M Cameron 2
 
View More
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.